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Recent years have seen a growing evidence of ethnic differences in the frequency of glutathione S-transferase 
omega 1 (GSTO1) A140D gene polymorphism, which is associated with various cancers such as breast 
and liver. Until now however, no association has been investigated between the GSTO1 A140D polymorphism 
and lung cancer. The aim of our study was to see if there was one in the Turkish population. To do that, 
we identiﬁ ed GSTO1 A140D polymorphism in 214 unrelated healthy individuals and 172 patients with 
non-small cell lung cancer (NSCLC) using the polymerase chain reaction - restriction fragment length 
polymorphism (PCR-RFLP) method. The frequencies of A/A (wild type), A/D (heterozygous mutant), and 
D/D (homozygous mutant) GSTO1 A140D genotypes in healthy subjects were 48 %, 41 %, and 11 %, 
respectively. In NSCLC patients they were 48 %, 45 %, and 7 %, respectively. We found no signiﬁ cant 
association between the GSTO1 A140D gene polymorphism and NSCLC or its histological subtypes, 
namely squamous cell carcinoma or adenocarcinoma. Furthermore, this polymorphism did not correlate 
with smoking. Our study is the ﬁ rst to show that the frequency of GSTO1 A140D gene polymorphism in 
the Turkish population is similar to other Caucasian populations and that this polymorphism is not associated 
with susceptibility to NSCLC.
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Glutathione S-transferases (GSTs) is a superfamily 
of enzymes that play a key role in the protection of 
cells against numerous xenobiotics (including 
carcinogens) and oxidative stress (1). Human cytosolic 
GSTs are divided into several classes according to 
their genetic and biochemical properties such as GST 
alpha, GST mu, GST theta, GST pi, and GST omega 
(2). Glutathione S-transferase omega 1 (GSTO1) is 
expressed in a wide range of human tissues, including 
the lungs (3, 4). It also plays a role in apoptosis (5, 6) 
and is a potential reservoir of intracellular glutathione 
248
(GSH), which protects against cellular oxidative stress 
(4, 5, 7).
The protective role against cell toxicity can be 
weakened if enzyme activity is reduced, but the 
ﬁ ndings related to the GSTO1 gene polymorphism 
Ala140Asp/A140D are still inconclusive; Tanaka-
Kagawa et al. (8) have shown that it signiﬁ cantly 
reduces thiol transferase activity whereas Whitbread 
et al. (9) and Board and Anders (10) could not ﬁ nd 
any significant reduction in the enzyme activity 
resulting from aspartic acid substitution.
The frequency of GSTO1 A140D seems to vary 
between races (9, 11-18), but only a few studies 
investigated this frequency in Caucasians (9, 14, 17, 
18). In the single study of GSTO1 A140D that included 
the Turkish population, Takeshita et al. (17) observed 
that its distribution differed from Caucasian 
populations, and was more similar to African, Eastern 
Asian, and Brazilian populations. However, this 
finding is challenged by a great variety in the 
distribution of the same gene polymorphism even 
within one population (19-22).
Recent studies have established an association 
between the GSTO1 A140D gene polymorphism and 
increased risk of breast, hepatocellular, bile duct, and 
urothelial cancer and acute lymphoblastic leukaemia 
in children (13, 23-25). In addition, several reports 
suggest that it may be associated with lung cancer in 
smokers (26-28). As about 80 % of the lung cancer 
patients are non-small cell lung cancer (NSCLC) (29) 
and cigarette smoke has an important impact on the 
development of its subtypes such as adenocarcinoma 
(AC) and squamous cell carcinoma (SCC) (30, 31), it 
would be important to know if there were any 
association between this gene polymorphism and the 
risk of NSCLC. However, to our knowledge, no data 
is available in this regard. The aim of our study was 
therefore to establish the frequency of the GSTO1 
A140D polymorphism in the Turkish population and 
see whether this polymorphism was associated with 
susceptibility to NSCLC and its histological 
subtypes.
SUBJECTS AND METHODS
The study population consisted of 214 healthy 
controls and 172 patients with a histological diagnosis 
of the primary stage III or IV NSCLC, who were 
receiving platinum-based chemotherapy, as described 
elsewhere (32, 33). All subjects were genotyped for 
the GSTO1 A140D polymorphism, as determined by 
the polymorphic analysis of genomic DNA isolated 
from whole blood using the Promega Corporation 
(Madison, WI, USA) DNA puriﬁ cation kit and stored 
at -20 °C until use. GSTO1 A140D (rs4925) was 
determined with polymerase chain reaction - restriction 
fragment length polymorphism (PCR-RFLP) method 
described by Marahatta et al. (13). Repeated quality 
control analysis of randomly chosen 10 % of the 
samples conﬁ rmed a 100 % match.
All subjects were native Turkish Caucasians. Most 
were from the central Turkey, but also from other 
Turkish regions to represent the whole country. 
Healthy unrelated controls were selected from the 
general population. The exclusion criteria were 
pregnancy and present or previous history of 
malignancy. All subjects gave written informed 
consent, and completed a questionnaire with 
information on their sex, smoking, occupation, and 
health history. The study was approved by a local 
ethics committee.
Statistical analysis
Statistical analysis was performed using the SPSS 
15.0 software (SPSS Inc., Chicago, IL, USA). We used 
Student’s t-test to see if the two groups differred in 
age and smoking (using pack-years as the measure). 
To establish differences in the distribution of genotype/
allele frequencies between the groups we used the 
chi-square test and Fisher’s exact test where necessary. 
The chi-square test was also used to see whether the 
frequency of the GSTO1 A140D polymorphism in 
either group ﬁ tted the Hardy-Weinberg equilibrium 
model. Multivariate logistic regression (34) was used 
to calculate the odds ratios (OR) and 95 % conﬁ dence 
intervals between the genotypes and lung cancer, 
adjusted for smoking status, sex, and age. P values 
less than 0.05 were assumed to be signiﬁ cant.
RESULTS AND DISCUSSION
Allele frequencies and genotype distribution of the 
GSTO1 A140D polymorphism in our study signiﬁ cantly 
differ from those of African, Brazilian, and Eastern 
Asian populations and are similar to other Caucasian 
populations (Table 1). In addition, our results are in 
contrast with the ﬁ ndings for the Turkish population 
reported by Takeshita et al. (17), whose genotype 
distribution and allele frequencies are similar to those 
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of African, Brazilian, and Eastern Asian populations. 
This is rather unexpected because polymorphism 
frequencies of xenobiotic metabolising enzyme genes 
studied in the Turkish population so far, namely CYP, 
mEH, and GST, are generally similar to other 
Caucasian populations (20-22, 35). At this stage, we 
can only speculate about the reasons why our ﬁ ndings 
differ, as both studies used the same methods, and 
sample sizes were similar. However, Takeshita et al. 
(17) have not included important demographic 
information on their Turkish native-borns such as age, 
sex, race, and exclusion criteria with respect to the 
health status. The only information they have provided 
is that their population included native-borns of the 
Table 1 Allele frequencies and genotype distribution of the GSTO1 A140D polymorphism in different populations
Population  n Allele frequency Genotype / n (%) ReferenceA140 D140 A/A A/D D/D
German 280 0.680 0.320 126 (46) 129 (46) 25 (9) 14
Italian 116 0.698 0.302 50 (43) 62 (53) 4 (3) 18
White American 735 0.655 0.345 319 (44) 315 (43) 93 (13) 12
White American 220 0.666 0.334 96 (44) 101 (46) 23 (11) 15
European Australian 100 0.665 0.335 45 (45) 43 (43) 12 (12) 8
Chinese 215 0.853 0.137* 158 (73) 55 (26) 2 (1) 16
Chinese 100 0.835 0.165* 71 (71) 25 (25) 4 (4) 8
Thai 98 0.870 0.130* 74 (76) 23 (23) 1 (1) 13
African 62 0.919 0.081* 52 (84) 10 (16) 0 (0) 8
Japanese 102 0.892 0.108* 81 (79) 20 (20) 1 (1) 17
Mongol 243 0.872 0.128* 183 (75) 58 (24) 2 (1) 17
Ovambo (Namibia) 163 0.960 0.040* 150 (92) 13 (8) 0 (0) 17
Brazilian 173 0.899 0.101* 146 (84) 19 (11) 8 (5) 11
Turkish 194 0.915 0.085* 162 (83) 31 (16) 1 (1) 17
Turkish 214 0.689 0.311 104 (48) 87 (41) 23 (11) This study
* Signiﬁ cantly different when compared to this study (P<0.05).
Table 2 Characteristics of the study population
NSCLC patients (n=172) Healthy controls (n=214)
Age / years
Mean 56 49
Range 26 to 75 24 to 76
Gender / n (%)
Male 156 (91) 118 (55)
Female 16 (9) 96 (45)
Smoking status / n (%)
Never 15 (9) 87 (41)
Former 55 (32) 43 (20)
Current 102 (59) 84 (39)
Pack-years, mean* 56 15
Genotypes / n (%)
A/A 48 (82) 48 (104)
A/D 45 (77) 41 (87)
D/D 7 (13) 11 (23)
NSCLC stage / n (%)
III 77 (45)
IV 95 (55)
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city of Adana in Turkey, whose data they received 
from a German physician.
Characteristics of the study population are 
presented in Table 2. As a group, NSCLC patients 
were older and had more smokers than controls 
(P<0.05). In addition, they smoked much more than 
controls (P<0.05). However, we did not ﬁ nd signiﬁ cant 
differences in the frequency of GSTO1 A/A (wild type), 
A/D (heterozygous mutant), and D/D (homozygous 
mutant) genotypes between NSCLC patients and 
controls, and they remained in the Hardy-Weinberg 
equilibrium (P=0.456 vs. P=0.379, respectively). No 
signiﬁ cant difference was also observed between men 
and women (data not shown).
We also looked into the distribution of GSTO1 
genotypes by histological subtypes in NSCLC patients 
but saw no statistically signiﬁ cant difference between 
controls and NSCLC or histological subtypes (data 
not shown). Using multivariate logistic regression 
(MLR) analysis adjusted for age, sex, and smoking, 
we established that GSTO1 genotypes presented no 
risk for overall NSCLC or a particular histological 
subtype. Likewise, Granja et al. (11) and Marahatta 
et al. (13) did not ﬁ nd any association between this 
gene polymorphism and thyroid and colorectal 
cancers, respectively. Findings are still inconclusive 
and controversial, as some authors established an 
increased risk of breast, hepatocellular, bile duct and 
urothelial cancers, and acute lymphoblastic leukaemia 
in childhood in GSTO1 A140D mutant allele carries 
(13, 23-25) while more recent studies on breast cancer 
report no such association (36, 37).
Using MLR, we also established that smoking did 
not inﬂ uence the relationship between GSTO1 A140D 
and the risk of NSCLC (Table 3). However, smoking 
alone, independent of the genotype, signiﬁ cantly 
increased the risk of NSCLC (Table 2). Likewise, 
Olsen et al. (23) could not detect any interaction 
between cigarette smoking and GSTO1 A140D in 
breast cancer, nor could Ada et al. (33) and Schneider 
et al. (38) establish an association between cigarette 
smoking and other GST polymorphisms in lung cancer, 
including NSCLC.
Our study may be limited by the sample size, 
especially in the analysis of the association between 
the polymorphism and cancer risk in the histological 
subtypes. However, this is the ﬁ rst report showing that 
the frequency of the GSTO1 A140D gene polymorphism 
in the Turkish population is similar to other Caucasian 
populations and that this polymorphism is not 
associated with susceptibility to NSCLC. Further 
research with a larger sample size is needed to verify 
this ﬁ nding.
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Sažetak
POVEZANOST POLIMORFIZMA A140D GENA GLUTATION S-TRANSFERAZE OMEGA 1 I 
OSJETLJIVOSTI NA RAK PLUĆA NE-MALIH STANICA U TURSKOG STANOVNIŠTVA
Posljednjih godina sve više rezultata ispitivanja upozorava na rasne razlike u učestalosti polimorﬁ zma 
A140D gena glutation S-transferaze omega 1 (GSTO1) koji je povezan s više oblika karcinoma, poput raka 
dojke i jetara. Dosada međutim nije ispitana povezanost GSTO1 A140D i raka pluća. Mi smo u ovom 
ispitivanju pokušali utvrditi postoji li takva povezanost u turskog stanovništva. Izdvojili smo 214 zdravih 
ispitanika koji nisu bili u rodu te 172 bolesnika s rakom pluća ne-malih stranica, u kojih je polimorﬁ zam 
GSTO1 A140D utvrđen pomoću lančane reakcije polimerazom - cijepanjem restrikcijskim enzimima 
(PCR/RFLP). Učestalost GSTO1 A140D genotipova - divljeg tipa (A/A), heterozigotnog mutanta (A/D) 
odnosno homozigotnog mutanta (D/D) - u zdravih ispitanika iznosila je 48 %, 41 %, odnosno 11 %, a u 
bolesnika s rakom pluća ne-malih stanica 48 %, 45 % odnosno 7 %. Rezultati ispitivanja nisu pokazali 
značajne povezanosti između genskog polimorﬁ zma GSTO1 A140D i raka pluća ne-malih stanica odnosno 
njegovih histoloških podtipova raka pločastih stanica ili adenokarcinoma. Također nisu pokazali povezanost 
između ovog polimorﬁ zma i pušenja. Međutim, ovo je prvo ispitivanje koje je potvrdilo da učestalost 
GSTO1 A140D u turske populacije odgovara učestalosti pripadnika bijele (kavkaske) rase te da nije povezan 
s osjetljivosti na rak pluća ne-malih stanica.
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